Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib combined with pirfenidone for bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation
ChiCTR2000038447Phase 4Not yet recruiting
- Sponsor
- Sichuan Provincial People's Hospital
- Start
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ibrutinib and pirfenidone in Bronchiolitis Obliterans Syndrome (BOS), sponsored by Sichuan Provincial People's Hospital. Primary endpoints: overall response rate, minimal residual disease remission and 4 more. Planned start Sep 2020; status: not yet recruiting.
02
Drugs
ibrutinibpirfenidone
03
Conditions
Bronchiolitis Obliterans Syndrome (BOS)
Beyond the preview
Go deeper on ChiCTR2000038447.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000038447.